Loading...
Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after che...
Na minha lista:
Udgivet i: | Front Oncol |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Frontiers Media S.A.
2020
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7253725/ https://ncbi.nlm.nih.gov/pubmed/32528889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00808 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|